IBDEI35F ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,52862,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52862,1,3,0)
 ;;=3^Diabetes d/t Underlying Conditions w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,52862,1,4,0)
 ;;=4^E08.621
 ;;^UTILITY(U,$J,358.3,52862,2)
 ;;=^5002534
 ;;^UTILITY(U,$J,358.3,52863,0)
 ;;=T81.33XA^^243^2650^27
 ;;^UTILITY(U,$J,358.3,52863,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52863,1,3,0)
 ;;=3^Disruption Traumatic Inj/Wound Repair,Init Encntr
 ;;^UTILITY(U,$J,358.3,52863,1,4,0)
 ;;=4^T81.33XA
 ;;^UTILITY(U,$J,358.3,52863,2)
 ;;=^5054476
 ;;^UTILITY(U,$J,358.3,52864,0)
 ;;=L60.3^^243^2650^30
 ;;^UTILITY(U,$J,358.3,52864,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52864,1,3,0)
 ;;=3^Dystrophic Nails
 ;;^UTILITY(U,$J,358.3,52864,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,52864,2)
 ;;=^5009236
 ;;^UTILITY(U,$J,358.3,52865,0)
 ;;=M71.30^^243^2650^25
 ;;^UTILITY(U,$J,358.3,52865,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52865,1,3,0)
 ;;=3^Digital Mucous Cyst
 ;;^UTILITY(U,$J,358.3,52865,1,4,0)
 ;;=4^M71.30
 ;;^UTILITY(U,$J,358.3,52865,2)
 ;;=^5013149
 ;;^UTILITY(U,$J,358.3,52866,0)
 ;;=L30.4^^243^2651^9
 ;;^UTILITY(U,$J,358.3,52866,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52866,1,3,0)
 ;;=3^Erythema Intertrigo
 ;;^UTILITY(U,$J,358.3,52866,1,4,0)
 ;;=4^L30.4
 ;;^UTILITY(U,$J,358.3,52866,2)
 ;;=^5009157
 ;;^UTILITY(U,$J,358.3,52867,0)
 ;;=R60.0^^243^2651^6
 ;;^UTILITY(U,$J,358.3,52867,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52867,1,3,0)
 ;;=3^Edema,Localized
 ;;^UTILITY(U,$J,358.3,52867,1,4,0)
 ;;=4^R60.0
 ;;^UTILITY(U,$J,358.3,52867,2)
 ;;=^5019532
 ;;^UTILITY(U,$J,358.3,52868,0)
 ;;=L53.0^^243^2651^13
 ;;^UTILITY(U,$J,358.3,52868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52868,1,3,0)
 ;;=3^Erythema Toxic
 ;;^UTILITY(U,$J,358.3,52868,1,4,0)
 ;;=4^L53.0
 ;;^UTILITY(U,$J,358.3,52868,2)
 ;;=^5009207
 ;;^UTILITY(U,$J,358.3,52869,0)
 ;;=L53.1^^243^2651^8
 ;;^UTILITY(U,$J,358.3,52869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52869,1,3,0)
 ;;=3^Erythema Annulare Centrifugum
 ;;^UTILITY(U,$J,358.3,52869,1,4,0)
 ;;=4^L53.1
 ;;^UTILITY(U,$J,358.3,52869,2)
 ;;=^5009208
 ;;^UTILITY(U,$J,358.3,52870,0)
 ;;=L51.9^^243^2651^11
 ;;^UTILITY(U,$J,358.3,52870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52870,1,3,0)
 ;;=3^Erythema Multiforme,Unspec
 ;;^UTILITY(U,$J,358.3,52870,1,4,0)
 ;;=4^L51.9
 ;;^UTILITY(U,$J,358.3,52870,2)
 ;;=^336759
 ;;^UTILITY(U,$J,358.3,52871,0)
 ;;=L12.35^^243^2651^7
 ;;^UTILITY(U,$J,358.3,52871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52871,1,3,0)
 ;;=3^Epidermolysis Bullosa,Acquired
 ;;^UTILITY(U,$J,358.3,52871,1,4,0)
 ;;=4^L12.35
 ;;^UTILITY(U,$J,358.3,52871,2)
 ;;=^5009100
 ;;^UTILITY(U,$J,358.3,52872,0)
 ;;=L52.^^243^2651^12
 ;;^UTILITY(U,$J,358.3,52872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52872,1,3,0)
 ;;=3^Erythema Nodosum
 ;;^UTILITY(U,$J,358.3,52872,1,4,0)
 ;;=4^L52.
 ;;^UTILITY(U,$J,358.3,52872,2)
 ;;=^42065
 ;;^UTILITY(U,$J,358.3,52873,0)
 ;;=L49.0^^243^2651^24
 ;;^UTILITY(U,$J,358.3,52873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52873,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ < 10% Body Surface
 ;;^UTILITY(U,$J,358.3,52873,1,4,0)
 ;;=4^L49.0
 ;;^UTILITY(U,$J,358.3,52873,2)
 ;;=^5009190
 ;;^UTILITY(U,$J,358.3,52874,0)
 ;;=L49.1^^243^2651^15
 ;;^UTILITY(U,$J,358.3,52874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52874,1,3,0)
 ;;=3^Exfoliation d/t Erythematous Cond w/ 10-19% Body Surface
 ;;^UTILITY(U,$J,358.3,52874,1,4,0)
 ;;=4^L49.1
 ;;^UTILITY(U,$J,358.3,52874,2)
 ;;=^5009191
 ;;^UTILITY(U,$J,358.3,52875,0)
 ;;=L49.2^^243^2651^16
 ;;^UTILITY(U,$J,358.3,52875,1,0)
 ;;=^358.31IA^4^2
